Feedback / Questions
talacotuzumab (JNJ-56022473) - J&J
Talacotuzumab: "Reduction in blast counts in peripheral blood after one dose"
(Johnson and Johnson Ltd)
-
May 21, 2017 -
Pharmaceutical Business Review
Clinical data
•
Acute Myelogenous Leukemia
http://files.shareholder.com/downloads/JNJ/4507568279x0x943361/95AFD3A4-424F-478E-9914-6CBAF56D2D06/Peter_Lebowitz_Slides.pdf
May 21, 2017
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious